Zoryl-M 4 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This fixed-dose formulation offers a synergistic effect, targeting multiple pathophysiological defects of type 2 diabetes. Zoryl-M 4 Forte Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent do not achieve adequate glycemic control. The extended-release formulation allows for once-daily dosing, improving patient compliance. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as the risk of hypoglycemia primarily due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction, metabolic acidosis, and hypersensitivity to the components. This medication should be used under strict medical supervision with appropriate lifestyle modifications to optimize diabetes management.